RAPID (NCT03464019) was a randomized, double-blind, event-driven, placebo-controlled Phase 3 study evaluating a single or repeat 70 mg dose of etripamil, self-administered by patients during a perceived PSVT episode, with a repeat dose permitted per protocol. Episodes were adjudicated from ambulatory ECG recordings. The efficacy population included patients who self-administered study drug during an adjudicated, confirmed, AV nodal-dependent PSVT episode; patients with post-conversion dosing, non-AV nodal-d ...